Antibodies

10 Sep 2017 Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
10 Sep 2017 Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017
10 Sep 2017 Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress
10 Sep 2017 Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
10 Sep 2017 Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy
09 Sep 2017 Celltrion Healthcare: Biosimilar Trastuzumab Candidate, CT-P6, Shown to Be Similar in Efficacy and Safety to Reference Trastuzumab in Breast Cancer Patients as Neoadjuvant and Adjuvant Treatment
09 Sep 2017 Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
09 Sep 2017 Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
09 Sep 2017 AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
08 Sep 2017 Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance”
08 Sep 2017 Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress
08 Sep 2017 Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
08 Sep 2017 Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
08 Sep 2017 Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC
08 Sep 2017 Conclusion of development collaboration agreement for Opdivo® (nivolumab) and Lenvima® (lenvatinib mesylate) combination therapy for treatment of hepatocellular carcinoma
08 Sep 2017 Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
07 Sep 2017 TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma
07 Sep 2017 InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa
07 Sep 2017 Celgene and AstraZeneca provide update on the FUSION clinical trial programme
07 Sep 2017 CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
07 Sep 2017 Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma
07 Sep 2017 Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
06 Sep 2017 Valerion Presents Preclinical Proof-of-Concept Data for VAL-0417 for the Treatment of Lafora Disease
06 Sep 2017 Tikcro Technologies Announces Full Human CTLA-4 Blocking Antibodies
06 Sep 2017 MacroGenics Advances Two First-in-Class Clinical DART® Molecules

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top